Adam Michael Deane

Adam Michael Deane

Auto-generated profile, based on publicly available information

Adam Michael Deane

Department of Critical Care, Melbourne Medical School, the University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2017 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
EFESICM Working Group on Gastrointestinal Function
ESICM Working Group on Gastrointestinal Function
ABAnnika Reintam Blaser
Annika Reintam Blaser
JSJoel Starkopf
Joel Starkopf
WAWaleed Alhazzani
Waleed Alhazzani
MBMette M. Berger
Mette M. Berger
HSHeleen M. Oudemans-Van Straaten
Heleen M. Oudemans-Van Straaten
Purpose To provide evidence-based guidelines for early enteral nutrition (EEN) during critical illness. Methods We aimed to compare EEN vs. early parenteral nutrition (PN) and vs. delayed EN. We defined “early” EN as EN started within 48 h independent of type or amount. We listed, a priori, conditions in which EN is often delayed, and performed systematic reviews in 24 such subtopics. If sufficient evidence was available, we performed meta-analyses; if not, we qualitatively summarized the evidence and based our recommendations on expert opinion. We used the GRADE approach for guideline development. The final recommendations were compiled via Delphi rounds. Results We formulated 17 recommendations favouring initiation of EEN and seven recommendations favouring delaying EN. We performed five meta-analyses: in unselected critically ill patients, and specifically in traumatic brain injury, severe acute pancreatitis, gastrointestinal (GI) surgery and abdominal trauma. EEN reduced infectious complications in unselected critically ill patients, in patients with severe acute pancreatitis, and after GI surgery. We did not detect any evidence of superiority for early PN or delayed EN over EEN. All recommendations are weak because of the low quality of evidence, with several based only on expert opinion. Conclusions We suggest using EEN in the majority of critically ill under certain precautions. In the absence of evidence, we suggest delaying EN in critically ill patients with uncontrolled shock, uncontrolled hypoxaemia and acidosis, uncontrolled upper GI bleeding, gastric aspirate >500 ml/6 h, bowel ischaemia, bowel obstruction, abdominal compartment syndrome, and high-output fistula without distal feeding access.

19 March 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
MSMiet Schetz
Miet Schetz
AJAudrey De Jong
Audrey De Jong
ADAdam M. Deane
Adam M. Deane
WDWilfried Druml
Wilfried Druml
PHPleun Hemelaar
Pleun Hemelaar
SJSamir Jaber
Samir Jaber

4 February 2020 in JAMA
Verified
Journal Article
Open access
PDF file
TFTomoko Fujii
Tomoko Fujii
NLNora Luethi
Nora Luethi
PYPaul J. Young
Paul J. Young
DFDaniel R. Frei
Daniel R. Frei
GEGlenn M. Eastwood
Glenn M. Eastwood
FIfor the VITAMINS Trial Investigators
for the VITAMINS Trial Investigators
Sepsis is a life-threatening illness characterized by a dysregulated host response to infection.1 It causes or contributes to between one-third and half of all hospital deaths2 and is responsible for more than 5 million deaths worldwide each year.3 Patients with septic shock are an important sepsis subgroup and have circulatory and metabolic abnormalities that substantially increase their mortality risk.4 For these patients in particular, new treatments that improve outcomes are a global public health priority.

1 June 2018 in Critical Care Medicine
Verified
Journal Article
Open access
JTJames A. Tumlin
James A. Tumlin
RMRaghavan Murugan
Raghavan Murugan
ADAdam M. Deane
Adam M. Deane
MOMarlies Ostermann
Marlies Ostermann
LBLaurence W. Busse
Laurence W. Busse
RBRinaldo Bellomo
Rinaldo Bellomo
Objective: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy. Design: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial. Setting: ICUs. Patients: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (n = 45 and n = 60, respectively). Interventions: IV angiotensin II or placebo. Measurements and Main Results: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%–67%) and 30% (95% CI, 19%–41%) in patients treated with angiotensin II and placebo (p = 0.012), respectively. By day 7, 38% (95% CI, 25%–54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%–27%) placebo (p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%–68%) and 22% (95% CI, 12%–34%) of patients treated with angiotensin II and placebo (p = 0.001), respectively. Conclusions: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.

25 November 2014 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
LPLiza K. Phillips
Liza K. Phillips
ADAdam M. Deane
Adam M. Deane
KJKaren L Jones
Karen L Jones
CRChris K. Rayner
Chris K. Rayner
Michael HorowitzMichael Horowitz
Michael Horowitz

17 March 2014 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
UGUsha Gungabissoon
Usha Gungabissoon
KHKimberley Hacquoil
Kimberley Hacquoil
CBChanchal Bains
Chanchal Bains
MIMichael Irizarry
Michael Irizarry
GDGeorge Dukes
George Dukes
Daren HeylandDaren Heyland
Daren Heyland